MedTrace Logo

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

NCT02897765 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2021-02-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate if the treatment with NEO-PV-01 + adjuvant in combination with nivolumab is safe and useful for patients with certain types of cancer. The study also will investigate if NEO-PV-01 + adjuvant with nivolumab may represent a substantial improvement over other available therapies such as nivolumab alone. All eligible patients will receive NEO-PV-01 + adjuvant and nivolumab while on this trial.

Conditions

  • Urinary Bladder Cancer
  • Bladder Tumors
  • Transitional Cell Carcinoma of the Bladder
  • Malignant Melanoma
  • Melanoma
  • Skin Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Cancer

Interventions

BIOLOGICAL

NEO-PV-01

Personal cancer vaccine

BIOLOGICAL

Nivolumab

monoclonal antibody against PD1

OTHER

Adjuvant

immune adjuvant

Sponsors & Collaborators

Principal Investigators

  • Mark DeMario, MD · BioNTech US Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2019-02-28
Completion
2020-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02897765 on ClinicalTrials.gov